Development of a deimmunized bispecific immunotoxin dDT2219 against B-cell malignancies

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Diphtheria toxin (DT) related targeted toxins are effective in cancer treatment, but efficacy diminishes in time because of their immunogenic potential and/or former vaccinations. In order to overcome this limitation for DT2219, a promising bispecific targeted toxin which targets CD19 and CD22, we deimmunized the DT moiety, and thereby developed an exciting improved drug (dDT2219) which still has the potential to sufficiently target B-cell malignancies but also limits clearance because of its reduced immunogenicity. The DT moiety was modified by inducing point mutations in prominent positions on the molecular surface. The new engineered dDT2219 was tested for activity, efficacy, and specificity using functional assays, proliferation assays, and flow cytometry. Furthermore, 12 samples of Chronic Lymphatic Leukemia (CLL) patients were used to assess binding. Immunogenicity was determined using a BALB/c mouse model. dDT2219 was efficient and specific against B-cell malignancies such as Bukitt-Lymphoma cell lines Daudi and Raji. dDT2219 showed specific binding on targets and on CLL samples. Intraperitoneal vaccination of immune competent mice showed that even after multiple administrations with increasing doses, induction of neutralizing antibodies was significantly lower in the dDT2219 treated animal group. The new dDT2219 combines potent anti-tumor cell activity with a reduced immunogenicity. With regard to the frequent development of neutralizing antibodies after multiple administrations with immunotoxins, dDT2219 shows promise to overcome this limitation and thus might maintain effectiveness even after multiple treatment cycles.

Original languageEnglish (US)
Article number32
JournalToxins
Volume10
Issue number1
DOIs
StatePublished - Jan 6 2018

Keywords

  • B-cell malignancies CD19
  • CD22
  • Deimmunized
  • Diphtheria toxin
  • Immunotoxin

Fingerprint Dive into the research topics of 'Development of a deimmunized bispecific immunotoxin dDT2219 against B-cell malignancies'. Together they form a unique fingerprint.

  • Cite this